Skip to main content may receive compensation from affiliate partners for some links on the site. Read our full Disclosure here.

Are Hospitals Getting Bonuses to Prescribe Remdesivir to COVID-19 Positive Medicare Patients?


Let’s review the scandal Dr. Bryan Ardis exposed about hospital protocols for COVID-19 patients.

From my previous report on the impact of the antiviral drug Remdesivir:

Hospital protocols, and not COVID-19, have accounted for a significant portion of deaths.

One of the biggest culprits is the drug Remdesivir.

The antiviral drug manufactured by Gilead Sciences has remained a central component of the standard hospital protocol for COVID-19 patients.

But the toxic drug is responsible for catastrophic side effects like multi-organ-dysfunction syndrome and kidney failure.

None other than Anthony Fraudci and his NIH cronies were behind pushing the dangerous drug for COVID-19 patients.

In his presentations, Dr. Ardis exposes the corruption behind the usage of Remdesivir as a COVID-19 treatment.

Here’s a brief rundown:

Here’s a backup on Rumble from the interview with Dr. Ardis on The Stew Peters Show:

Common sense and moral decency would tell us that Remdesivir should go into the garbage can, let alone as a treatment for any illness.

But we live in a world of sinister corruption driven by financial gain.

A page on the CMS website shows blatant bribery to prescribe Remdesivir to COVID-positive patients.

In case you’re unfamiliar with the CMS, here’s a brief description of the federal agency.

From Wikipedia:

TheĀ Centers for Medicare & Medicaid ServicesĀ (CMS), is a federal agency within theĀ United States Department of Health and Human ServicesĀ (HHS) that administers theĀ MedicareĀ program and works in partnership with state governments to administerĀ Medicaid, theĀ Children’s Health Insurance ProgramĀ (CHIP), andĀ health insuranceĀ portability standards. In addition to these programs, CMS has other responsibilities, including the administrative simplification standards from theĀ Health Insurance Portability and Accountability ActĀ of 1996 (HIPAA), quality standards inĀ long-term careĀ facilities (more commonly referred to asĀ nursing homes) through its survey and certification process, clinical laboratory quality standards under theĀ Clinical Laboratory Improvement Amendments, and oversight ofĀ CMS was previously known as the Health Care Financing Administration (HCFA) until 2001.

There’s a page on the CMS website that shows an add-on payment (bribe) coding for Remdesivir as a COVID-19 treatment.

From the CMS page titled, “New COVID-19 Treatments Add-On Payment (NCTAP)”

CMS issued anĀ Interim Final Rule with Comment PeriodĀ that established the New COVID-19 Treatments Add-on Payment (NCTAP) under the Medicare Inpatient Prospective Payment System (IPPS). The NCTAP, designed to mitigate potential financial disincentives for hospitals to provide new COVID-19 treatments, is effective from November 2, 2020, until the end of the COVID-19 public health emergency (PHE).

Through the NCTAP, the Medicare Program will provide an enhanced payment for eligible inpatient cases that useĀ certain new products with current FDAĀ approval or emergency use authorization (EUA) to treat COVID-19, including the following:

  • On August 23, 2020, the FDA issued (reissued on November 30, 2020, and revised on March 9, 2021) anĀ EUA for the use of COVID-19 convalescent plasmaĀ for treating COVID-19 in hospitalized patients
  • On October 22, 2020, theĀ FDA approved remdesivir (Veklury)Ā for the treatment of COVID-19 for adults and certain pediatric patients requiring hospitalization
  • On November 19, 2020, the FDA issued anĀ EUA for the use of baricitinib (Olumiant), in combination with remdesivir (Veklury), for the treatment of suspected or laboratory confirmed COVID-19 in certain hospitalized patients

For eligible cases, the NCTAP is equal to the lesser of these:

  • 65% of the operating outlier threshold for the claim
  • 65% of the amount by which the costs of the case exceed the standard Diagnosis-Related Group (DRG) payment (including the adjustment to the relative weight underĀ Section 3710 of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act)

Coding for NCTAP

NCTAP claims are those that are eligible for the 20% add-on payment under Section 3710 of the CARES Act. Eligible claims have both of the following:

  • ICD-10-CM diagnosis code U07.1 (COVID-19)
  • ICD-10-PCS codes for remdesivir (Veklury), COVID-19 convalescent plasma, or baricitinib (Olumiant) in combination with remdesivir, as described below


Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!

We Love Trump
Thanks for sharing!
Send this to a friend